Mohammed Hussain, MD
Cardiovascular Disease · Chicago, ILNPI 1649339441
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,533 of the $4,608 with a category attached, or 76.7%. 31 manufacturers reported payments, led by AstraZeneca at 37.6% of the total. Reporting peaked in 2024 at $1,918 and has fallen 92.3% since, to $147 in 2025.
Across 164 payments — averaging $28.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- E.r. Squibb & Sons, L.L.C.$259
- Novo Nordisk$245
- Kowa Pharmaceuticals America, Inc.$229
- Johnson & Johnson$222
- Boehringer Ingelheim$207
- plus $2K from 25 others
Across 1 payment — averaging $34,988 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$35K
What the payments were for
- Travel & lodging$1,07523%
- Food & beverage$3,53377%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 25 | $1,734 |
| E.r. Squibb & Sons, L.L.C. | 16 | $259 |
| Novo Nordisk | 13 | $245 |
| Kowa Pharmaceuticals America, Inc. | 12 | $229 |
| Johnson & Johnson | 11 | $222 |
| Boehringer Ingelheim | 11 | $207 |
| Astellas Pharma US Inc | 10 | $181 |
| Pfizer | 8 | $166 |
| Preventric Diagnostics, Inc. | 2 | $154 |
| Novartis | 8 | $124 |
| Neurocrine Biosciences, Inc. | 1 | $113 |
| GSK | 6 | $108 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $99 |
| Lilly USA, LLC | 4 | $72 |
| Exact Sciences | 3 | $68 |
| Eisai Inc. | 4 | $66 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $65 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $63 |
| Ardelyx, Inc. | 2 | $59 |
| Amarin Pharma, Inc. | 4 | $58 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $50 |
| Lexicon Pharmaceuticals, Inc. | 2 | $48 |
| Ascensia Diabetes Care US Inc. | 1 | $45 |
| UCB, Inc. | 1 | $43 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Pharmaessentia USA Corporation | 1 | $20 |
| AbbVie | 1 | $20 |
| Merck | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Lucid Diagnostics Inc. | 1 | $15 |
| Itamar Medical Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$113
How this compares
$4,608 in reported general payments places this provider in the 70th percentile of 932 cardiovascular disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 163 | $157,848 |
| EliquisApixaban | 134 | $131,429 |
| OtezlaApremilast | 25 | $61,983 |
| LinzessLinaclotide | 93 | $54,802 |
| EpidiolexCannabidiol (Cbd) | 29 | $50,501 |
| EntrestoSacubitril/Valsartan | 26 | $38,888 |
| Invega SustennaPaliperidone Palmitate | 13 | $32,657 |
| TradjentaLinagliptin | 22 | $31,532 |
| BrilintaTicagrelor | 33 | $31,525 |
| XareltoRivaroxaban | 30 | $29,479 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $22,715 |
| JanuviaSitagliptin Phosphate | 17 | $15,943 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $15,742 |
| FarxigaDapagliflozin Propanediol | 12 | $13,236 |
| ZenpepLipase/Protease/Amylase | 24 | $10,714 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $207 | $189,379185 claims |
| PfizerEliquis | $166 | $131,429134 claims |
| Johnson & JohnsonInvega Sustenna, Xarelto | $222 | $62,13643 claims |
| AbbVieLinzess | $20 | $54,80293 claims |
| AstraZenecaBrilinta, Farxiga, Symbicort | $1,734 | $47,70857 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $108 | $41,41153 claims |
| NovartisEntresto | $124 | $38,88826 claims |
| MerckJanuvia | $18 | $15,94317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 932 cardiovascular disease providers in Illinois.
Other cardiovascular disease in Chicago
- Sandeep NathanChicago$892K
- Boaz AvitallChicago$366K
- Akhil NarangChicago$363K
- Michael DavidsonChicago$317K
- Jyothy PuthumanaChicago$269K
- Sanjiv ShahChicago$246K
- Raja MutharasanChicago$146K
- Nitasha SarswatChicago$140K
- Evan SteinChicago$121K
- Dan FintelChicago$119K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.